Sep 12, 2026 · 18 min
Shorter antibiotics challenge a medical rule as fibromyalgia genetics emerge
Is a shorter course of antibiotics OK? + Genetic risk of fibromyalgia
The episode connects antibiotic stewardship with new genetic evidence that may reshape how fibromyalgia is understood and treated.
- 1Shorter, targeted antibiotic courses may protect the microbiome while reducing C. diff and resistance risks.
- 2A large study found 26 fibromyalgia-linked variants, but genetics explains only a modest share of overall risk.
- 3The findings point toward nervous-system biology and possible treatment targets without supporting genetic screening yet.
Don't miss
Nasa Sinnott-Armstrong explains why 26 genetic variants offer biological clues about fibromyalgia without yet supporting genetic screening.
The brief
The traditional instruction to always finish an antibiotic prescription is being reconsidered as longer treatment can disrupt the microbiome, encourage resistance, and raise C. diff risk.
Amy Morris explains how updated guidelines and prescribing habits are shifting toward shorter, targeted courses, while leaving room for clinical judgment about the infection being treated.
Nasa Sinnott-Armstrong discusses a study identifying 26 fibromyalgia-associated variants; the inherited contribution is modest, but the signal points toward nervous-system biology.
The genetic results do not justify screening yet, but they may clarify nociplastic pain, possible triggers such as stress or infection, and future targets including GPR52.
Featuring
Listen to the full episode and explore every guest, topic, and moment on PodLume.